Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three blockbuster Weight-Loss drugs go Head-to-Head in diabetic and Non-Diabetic adults

NCT ID NCT07820111

Disease control Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers compare three weekly GLP-1 receptor agonists, dulaglutide, semaglutide, and tirzepatide, in 159 obese adults, 84 with diabetes and 75 without. Participants receive one of the drugs for 24 weeks. The trial measures changes in body weight, BMI, blood sugar, cholesterol, and liver enzymes at 3 and 6 months to see how the drugs differ between diabetic and non-diabetic people.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
weekly GLP-1 receptor agonist injections: dulaglutide, semaglutide, or tirzepatide
What this could lead to
If one drug works better for a specific group, doctors could tailor obesity and diabetes treatment more precisely. The results may also clarify how these drugs affect cholesterol and liver enzymes, not just weight.
What could go wrong
This is a single-center study of 159 people over 24 weeks, so differences between drugs may be small or fade with longer use. GLP-1 drugs commonly cause nausea, vomiting, and diarrhea, and some participants may stop treatment early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

159 people

The number who actually took part.

Started

Oct 2025

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * overweight or obese, diabetic, or non-diabetic Exclusion Criteria: * Patients who will refuse to be enrolled in the study or refuse to sign the consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese diabetics are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese diabetics Obese non diabetic

Contacts and locations

Locations

  • Najran Health Cluster

    Najran, Ksa, 55461, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.